Table 1.
CD229 expression in lymphomas and myeloma.
| Types of Lymphoma | No. Cases | Positive Cases | Negative Cases | % Positive Cases |
|---|---|---|---|---|
| Precursor neoplasms | ||||
| Precursor B lymphoblastic lymphoma | 7 | 2 | 5 | 28% |
| Mature B-Cell Neoplasms | ||||
| Chronic lymphocytic leukemia | 20 | 14 | 6 | 70% |
| Follicular lymphoma | 20 | 12 | 8 | 60% |
| Classic mantle-cell lymphoma | 20 | 14 | 6 | 70% |
| Diffuse large B-cell lymphoma GCB Type | 29 | 19 | 10 | 66% |
| Diffuse large B-cell lymphoma Non-GCB type | 19 | 10 | 9 | 52% |
| Burkitt lymphoma | 20 | 4 | 16 | 20% |
| Nodal marginal-zone lymphoma | 34 | 28 | 6 | 82% |
| MALT lymphoma | 28 | 24 | 4 | 86% |
| Splenic marginal-zone lymphoma | 15 | 13 | 2 | 87% |
| Multiple myeloma 1 | 20 | 20 | 0 | 100% |
| Hodgkin Lymphomas | ||||
| Nodular lymphocyte-predominant HL | 7 | 0 | 7 | 0% |
| Lymphocyte-rich cHL | 3 | 0 | 3 | 0% |
| Nodular sclerosis cHL | 10 | 0 | 10 | 0% |
| Mixed cellularity cHL | 8 | 0 | 8 | 0% |
1 Bone marrow.